🏛️ Verified NIH Record • Updated 2026-07-15
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine (NCT06615375)
Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With the Shigella Tetravalent Bioconjugate Vaccine Shigella4V2
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: LimmaTech Biologics AG
🩺 Plain-English Summary (8th-Grade Level)
In this challenge study, the bioconjugate candidate vaccine Shigella4V2 will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella sonnei strain compared to participants receiving placebo.
Who can join: Review the eligibility criteria below.
Location: Hope Clinic of Emory University — Atlanta, Georgia
Age range: 18 Years to 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Hope Clinic of Emory University — Atlanta, Georgia
- Johns Hopkins Center for Immunization Research — Baltimore, Maryland
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Shigellosis
Explore by condition: All Shigellosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.